NASDAQ:BMRN

Biomarin Pharmaceutical Stock Insider Trading

Healthcare > Biotechnology

Buy BMRN

*Your capital is at risk

$56.50

+0.600 (+1.07%)

At Close: Jun 23, 2026

BioMarin Pharmaceutical Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 6.32. In total, the insiders bought 820.92K and sold 149.11K BMRN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	6.32
● Buy	820.92K shares
● Sell	149.11K shares
70% Buy Activity Moderate Negative Correlation
Buy Signal Low Confidence Mar 16, 2026 Analysis Breakdown: Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jun 02, 2026 Buy	Common Stock A-Award	Countouriotis Athena Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Walbert Timothy P Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Ho Maykin Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Hombach Robert J. Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Enyedy Mark J Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Dere Willard H Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Clark Ian T Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Bodem Barbara W. Director	Director	7 490 Value: $399.4K
Jun 02, 2026 Buy	Common Stock A-Award	Anderson Elizabeth M Director	Director	7 490 Value: $399.4K
May 20, 2026 Sell	Common Stock F-InKind	Hubbard Cristin EVP, Chief Commercial Officer	Officer	2 318 Value: $116.4K
May 07, 2026 Sell	Common Stock S-Sale	Friberg Gregory R EVP, Chief R&d Officer	Officer	3 281 Value: $176.7K
Mar 18, 2026 Sell	Common Stock F-InKind	Davis George Eric EVP, Chief Legal Officer	Officer	1 273 Value: $71.4K
Mar 17, 2026 Sell	Common Stock F-InKind	Hardy Alexander Chief Executive Officer	CEO / President	4 252 Value: $238.3K
Mar 17, 2026 Sell	Common Stock F-InKind	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	2 117 Value: $118.7K
Mar 17, 2026 Sell	Common Stock F-InKind	Guyer Charles Greg EVP, Chief Technical Officer	Officer	1 693 Value: $94.9K
Mar 17, 2026 Sell	Common Stock F-InKind	Friberg Gregory R EVP, Chief R&d Officer	Officer	1 629 Value: $91.3K
Mar 17, 2026 Sell	Common Stock F-InKind	Hubbard Cristin EVP, Chief Commercial Officer	Officer	1 245 Value: $69.8K
Mar 16, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Friberg Gregory R EVP, Chief R&d Officer	Officer	45 600 Value: $2.62M
Mar 16, 2026 Buy	Common Stock A-Award	Friberg Gregory R EVP, Chief R&d Officer	Officer	19 150 Value: $1.10M
Mar 16, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Hubbard Cristin EVP, Chief Commercial Officer	Officer	36 680 Value: $2.11M
Mar 16, 2026 Buy	Common Stock A-Award	Hubbard Cristin EVP, Chief Commercial Officer	Officer	15 410 Value: $885.0K
Mar 16, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Hardy Alexander Chief Executive Officer	CEO / President	89 200 Value: $5.12M
Mar 16, 2026 Buy	Common Stock A-Award	Hardy Alexander Chief Executive Officer	CEO / President	62 440 Value: $3.59M
Mar 16, 2026 Buy	Stock Option (Right to Buy Common Stock) A-Award	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	44 600 Value: $2.56M
Mar 16, 2026 Buy	Common Stock A-Award	Mueller Brian EVP, Chief Financial Officer	C-Suite Officer	18 740 Value: $1.08M

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT BIOMARIN PHARMACEUTICAL INC.

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...

Read Full Profile Here